CYNATA THERAPEUTICS ORDINARY (CYP) Short Interest
CYNATA THERAPEUTICS ORDINARY (ASX:CYP) had 0.00% of shares reported as short positions as of 11 July 2026, representing 3,127 shares. CYNATA THERAPEUTICS ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Unlock advanced features: Custom dashboards, portfolio tracking, real-time alerts, and more
Cynata Therapeutics
Cynata Therapeutics is a clinical-stage biotechnology company focused on developing and commercialising its proprietary Cymerus™ platform technology, which generates induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs). This innovative platform provides a scalable and consistent source of MSCs, positioning Cynata as a potential leader in 'off-the-shelf' regenerative medicine with applications across various inflammatory, autoimmune, and degenerative diseases.